Join our daily newsletter At The Bell to receive exclusive market insights
- Echo IQ (EIQ) is releasing six new cardiac decision-support solutions to expand its EchoSolv cardiology platform from November 2023-January 2024
- These solutions incorporate standard diagnostic guidelines designed to help doctors conduct more accurate assessments
- The current EchoSolv model offers solutions for Aortic Stenosis and Mitral Regurgitation, but now it will treat diastolic dysfunction, heart failure, hypertension and heart valve disorders
- These new products will see EIQ increase its addressable market
- EIQ shares are down 3.32 per cent, trading at 15 cents at 2:11 pm AEST
Echo IQ (EIQ) has announced plans to release six new cardiac decision-support solutions, significantly expanding its EchoSolv cardiology platform between November 2023 and January 2024.
These solutions incorporate standard diagnostic guidelines designed to assist doctors in conducting more accurate assessments. The current EchoSolv model only offers support for Aortic Stenosis and Mitral Regurgitation.
Echo’s upgraded platform will provide support for cardiologists in diagnosing and assessing diastolic dysfunction, heart failure, hypertension, and heart valve disorders with greater precision.
Echo IQ’s Chief Medical Advisor, Professor David Playford, emphasised the company’s commitment to applying new technologies to the complex field of echocardiography.
“These new enhancements to the EchoSolv platform simplify challenging diagnoses and present them to doctors providing even greater levels of decision-support,” he said.
“Having EchoSolv as the go-to decision-support system will improve a doctor’s accuracy of diagnosis and increase confidence to initiate life-saving interventions.”
With the addition of these new solutions for hard-to-diagnose heart conditions, EIQ is set to expand its addressable market. These products are scheduled for release in November, offering users easy-to-use, accessible decision-support tools for up to eight cardiac conditions and indicators, at an additional cost.
EIQ shares were down 3.32 per cent, trading at 15 cents at 2:11 pm AEST.
